BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/16/2024 6:17:54 AM | Browse: 143 | Download: 753
 |
Received |
|
2024-03-23 14:11 |
|
Peer-Review Started |
|
2024-03-23 14:11 |
|
First Decision by Editorial Office Director |
|
2024-05-03 19:39 |
|
Return for Revision |
|
2024-05-03 19:39 |
|
Revised |
|
2024-05-14 03:43 |
|
Publication Fee Transferred |
|
2024-06-18 02:59 |
|
Second Decision by Editor |
|
2024-06-14 02:42 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-06-14 08:09 |
|
Articles in Press |
|
2024-06-14 08:09 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-07-09 00:24 |
|
Publish the Manuscript Online |
|
2024-07-16 06:17 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Low testing rates and high BRCA prevalence: Poly (ADP-ribose) polymerase inhibitor use in Middle East BRCA/homologous recombination deficiency-positive cancer patients
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Naveed Syed, Ashish Vittalrao Chintakuntlawar, Deepti Vilasini, Aisha Mohamed Al Salami, Riad Al Hasan, Imrana Afrooz, Kanishka Uttam Chandani, Ashok Uttam Chandani and Aref Chehal |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Naveed Syed, Visiting Professor, Doctor, MBBS, Department of Hematology and Oncology, Sheikh Shakbout Medical City, Mafraq Area, Abu Dhabi 11001, United Arab Emirates. naveed3642003@gmail.com |
| Key Words |
Homologous recombination repair; BRCA1; BRCA2; Homologous recombination deficiency; Ovarian cancer; Breast cancer; Poly (ADP-ribose) polymerase inhibitors; Olaparib; DNA double-strand breaks |
| Core Tip |
Following National Comprehensive Cancer Network guidelines, breast cancer patients were tested for BRCA1/2 mutations, while ovarian cancer patients underwent homologous recombination defect testing. These mutations can be targeted with poly (ADP-ribose) polymerase inhibitor (PARPi) therapy, a form of precision medicine. In this single-center study, we analyzed the proportion of breast and ovarian cancer patients tested for mutations, demographics and disease characteristics of tested patients, and PARPi therapy outcomes. This first-of-its-kind study in the Middle East offers insights into targeted therapy use, contributing to knowledge on PARPis for breast and ovarian cancers. |
| Publish Date |
2024-07-16 06:17 |
| Citation |
Syed N, Chintakuntlawar AV, Vilasini D, Al Salami AM, Al Hasan R, Afrooz I, Uttam Chandani K, Chandani AU, Chehal A. Low testing rates and high BRCA prevalence: Poly (ADP-ribose) polymerase inhibitor use in Middle East BRCA/homologous recombination deficiency-positive cancer patients. World J Clin Oncol 2024; 15(7): 848-858 |
| URL |
https://www.wjgnet.com/2218-4333/full/v15/i7/848.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v15.i7.848 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
